Ex Parte Marshall et alDownload PDFPatent Trial and Appeal BoardApr 28, 201410630547 (P.T.A.B. Apr. 28, 2014) Copy Citation UNITED STATES PATENT AND TRADEMARK OFFICE __________ BEFORE THE PATENT TRIAL AND APPEAL BOARD __________ Ex parte MARK T. MARSHALL, TERESA A. WHITMAN, EDUARDO N. WARMAN, JEFFREY M. GILLBERG, MATTHEW D. BONNER, and MARK L. BROWN __________ Appeal 2012-001158 Application 10/630,547 Technology Center 3700 __________ Before DEMETRA J. MILLS, JEFFREY N. FREDMAN and ERICA A. FRANKLIN, Administrative Patent Judges. MILLS, Administrative Patent Judge. DECISION ON REHEARING Appellants have requested rehearing of the decision entered March 3, 2014 (“Decision”). The Decision affirmed rejections of claims for obviousness. We have reconsidered our Decision and the request for rehearing is granted. We have jurisdiction under 35 U.S.C. § 6(b). Appeal 2012-001158 Application 10/630,547 2 STATEMENT OF CASE Claim 1 is representative. 1. A medical system, comprising: an implantable cardiac pacing pulse generator; a first lead, comprising an elongated lead body including a first elongated insulated conductor and a first connector formed at a proximal end thereof; the connector including a first electrical contact electrically coupled at a first polarity to the pacing pulse generator; a second lead, comprising an elongated lead body including a second elongated insulated conductor and a second connector formed at a proximal end thereof; the connector including a second electrical contact electrically coupled at a second polarity to the pacing pulse generator, the pacing pulse generator comprising means for delivering pulses between the first and second electrical contacts; a first pacing electrode joined to the first lead body and coupled to the first contact of the first connector via the first conductor, the first electrode adapted for intimate contact with tissue at a first site; a second pacing electrode joined to the second lead body and coupled to the second contact of the second connector via the second conductor, the second electrode adapted for location at a second site; and a porous layer formed over the second electrode, allowing conduction therethrough while preventing contact between the second electrode and tissue in proximity to the second site. Discussion Prior to our rehearing discussion we note that the Appeal Brief, page 4, indicated that the invention was that the first electrode “is not provided with a porous coating,” and the “second pacing electrode” “includes a porous layer formed over the second electrode.” (id at 5.) The Examiner found, and we agreed, however, that the claims did not preclude the first electrode from having a porous coating (Spec. 3) which was taught by Carson. The only additional argument in the Brief was that the cited prior art “[n]either discloses nor suggests any benefit that might be obtained by Appeal 2012-001158 Application 10/630,547 3 delivering pacing stimulation between two electrodes of the two different types as set forth in the present claims.” (App. Br. 6.) Because patentability of a product depends upon its structure and not its intended use or benefit, and because the pending claims read upon the two porous electrodes of Carson, we found that the Examiner had established a prima facie case of obviousness. We had no other argument from Appellants regarding differences in the porous electrode structures which account for “intimate contact” or the “prevention of contact” of the electrodes. While features of an apparatus may be recited either structurally or functionally, claims directed to an apparatus must be distinguished from the prior art in terms of structure rather than function. In re Schreiber, 128 F.3d 1473, 1477-1478 (Fed. Cir. 1997). In the Request for Rehearing, Appellants clarify their position that it is not the porous nature of the electrodes that distinguishes their invention from the prior art. Indeed, Appellants acknowledge that their “Specification [discloses] a first porous electrode structure could provide intimate tissue contact. A second, different porous electrode structure could prevent tissue contact,” which is reflected in the pending claims. (Rehearing 3.) Appellants argue that, although in Carson, the two electrodes relied upon by the examiner (the atrial electrodes) are both coated with a porous coating, “[t]he porous coated electrode in Carson cannot simultaneously be ‘adapted for intimate contact with tissue at the site’ and be provided with a porous coating ‘preventing contact between the second electrode and tissue.’” (Reply Br. 3.) According to the Specification, the first electrode has a tine structure 880 “in order to maintain intimate contact . . . with tissue at an implant site.” Appeal 2012-001158 Application 10/630,547 4 (Spec. 5.) We therefore, interpret the first electrode recited in claim 1 as requiring some structure, such as a tine structure, to adapt the electrode for intimate contact with tissue. According to the Specification, page 7, the second electrode includes “a porous layer separating the second electrode from direct touching contact with tissue adjacent to an implant site.” The Specification does not require any structure in addition to a porous layer to provide this function. Therefore, we interpret the second electrode recited in claim 1 as not comprising any additional structure which would permit “direct touching” or “intimate contact”. Carson discloses that the electrode pore size may be chosen to be small enough to discourage tissue ingrowth (col. 4, ll. 1-3). Carson discloses an alternative embodiment wherein gelatin wets the ePTFE, expanding within the pores to prevent tissue adhesion (col. 9, ll. 1-9.) Thus, Carson reasonably discloses a porous electrode that prevents tissue contact, i.e., satisfying the second electrode recited in claim 1. The Examiner argued in the Answer, page 7, that It would have been obvious to one having ordinary skill in the art at the time of the invention to use separate leads for the separate electrodes, as taught by Helland et al, in the bipolar pacing system with electrode porous layer as disclosed by Carson, in order to allow for implantation in both the cardiac vein and the right ventricle for pacing/defibrillation therapy. Although Appellants admit that Helland discloses that it is known to use an uncoated electrode (App. Br. 6) and Carson discloses that it is known to use a coated electrode (id.) in an implantable device, what is missing from the Examiner’s analysis is why one of ordinary skill in the art would have been motivated to use two different types of electrodes as claimed, one Appeal 2012-001158 Application 10/630,547 5 providing intimate tissue contact and the other preventing contact, in an implantable cardiac pacing pulse generator. Therefore, the obviousness rejection is reversed for the reasons herein, and the requested relief is granted. No time period for taking any subsequent action in connection with this appeal may be extended under 37 C.F.R. § 1.136(a). GRANTED dm Copy with citationCopy as parenthetical citation